Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

42.57

Mkt cap

278B

Volume

213K

High

43.31

P/E Ratio

29.63

52-wk high

43.96

Low

42.56

Div yield

N/A

52-wk low

29.20

Several publicly traded companies are integrating artificial intelligence (AI) into their operations to catalyze transformations in the biotech and pharmaceutical sectors. These companies include Recursion Pharmaceuticals (RXRX), 23andMe (ME), Novartis (NVS), Roche (RHHBY), Pfizer (PFE), Johnson & Johnson (JNJ), Regeneron Pharmaceuticals (REGN), and Illumina (ILMN). The integration of AI is expected to enhance drug discovery, patient care, and other operations.

Portfolio Pulse from Steve Macalbry

September 11, 2023 | 5:27 pm

Alnylam Pharmaceuticals' KARDIA-1 Phase 2 study of zilebesiran, a drug for hypertension, has met its primary endpoint. The drug is being co-developed with Roche Holdings. The study showed a significant reduction in blood pressure and met key secondary endpoints. The results reaffirm the program's potential and could impact Ionis Pharmaceuticals, which is developing a similar therapeutic. Alnylam's shares are up 0.92%.

Portfolio Pulse from Vandana Singh

September 07, 2023 | 6:07 pm

The FDA has accepted the application of Roche's subsidiary Genentech's drug, Crovalimab, for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare life-threatening blood condition. This could potentially open a new revenue stream for Roche.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 6:43 am

Roche Holdings AG announced that its Phase 3 ALINA study evaluating Alecensa, compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival. Alecensa demonstrated a significant improvement in disease-free survival as adjuvant therapy in people with completely resected stage IB anaplastic lymphoma kinase-positive non-small cell lung cancer. The drug is now approved in over 100 countries as an initial treatment for ALK-positive, metastatic NSCLC, including in the United States, Europe, Japan, and China.

Portfolio Pulse from Vandana Singh

September 01, 2023 | 12:15 pm

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the National Health Service (NHS) to implement a seven-minute injection for cancer patients using Roche Holdings AG's Tencentriq (atezolizumab). The new method is quicker and more comfortable than the previous 30-minute to one-hour intravenous drug transfusion. The change will benefit approximately 3,600 patients annually in England. The treatment will come at no additional cost to the NHS due to an existing agreement with Roche.

Portfolio Pulse from Vandana Singh

August 30, 2023 | 3:37 pm

Roche's drug Evrysdi has received approval from the European Commission for the treatment of babies under two months old with Spinal Muscular Atrophy. This approval could potentially increase Roche's market share in the European pharmaceutical market.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 6:25 am

Roche Holdings inadvertently disclosed the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq for non-small cell lung cancer. The update boosted shares of Iteos Therapeutics and Arcus Biosciences, who are also working on TIGIT-blocking cancer treatments. Other companies working in this area include Gilead Sciences, Merck & Co, and BeiGene.

Portfolio Pulse from Vandana Singh

August 23, 2023 | 7:05 pm

Roche Holdings AG inadvertently disclosed the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq versus Tecentriq alone for advanced or metastatic non-small cell lung cancer. The study remains ongoing and blinded to patients and investigators. The leaked data showed encouraging results, with tiragolumab plus Tecentriq well-tolerated and no new safety signals identified. More solid survival results are expected in Q1 2024.

Portfolio Pulse from Vandana Singh

August 23, 2023 | 11:48 am

Shares of ITeos Therapeutics have risen by 32% in premarket trading following the release of Roche's non-small cell lung cancer (NSCLC) data.

Portfolio Pulse from Charles Gross

August 23, 2023 | 10:44 am

Shares of Arcus Biosciences surged 25% in premarket trading following the inadvertent release of preliminary results from a non-small cell lung cancer study by Roche. The impact of this news on Roche's stock is not mentioned.

Portfolio Pulse from Charles Gross

August 23, 2023 | 10:19 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.